Every 8-K that CLARITEV CORPORATION WTS (MPLNW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MPLNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MPLNW filings page.
Claritev Corporation furnished this report to address a media article about government scrutiny. The company explains that in August 2024 it received a confidential grand jury subpoena from the Antitrust Division of the Department of Justice in connection with an investigation regarding health insurance and has been cooperating fully. Claritev states that, over the subsequent two years, the DOJ has not informed the company that it is a target of the investigation. Management says it remains focused on working with healthcare clients and partners to improve transparency, access, and affordability, and includes standard cautionary language about forward-looking statements and legal risks.
Claritev Corporation reported mixed first-quarter 2026 results with modest growth but continued losses and heavy leverage. Revenues reached $244.7 million, up 5.8% from $231.3 million a year earlier, while Adjusted EBITDA rose 3.4% to $146.9 million, implying a 60.0% margin versus 61.4% in 2025.
The company posted a net loss of $73.6 million, slightly larger than the $71.3 million loss a year earlier, and net loss per share was $4.41. Operating cash flow was negative at $45.8 million and Free Cash Flow was a negative $92.5 million, reflecting high capital expenditures and interest costs.
Claritev ended the quarter with $21.3 million of unrestricted cash and total assets of about $4.84 billion against total liabilities of about $5.07 billion, resulting in a shareholders’ deficit. Management nudged full-year 2026 revenue guidance up to a range of $985 million to $1.0 billion, while keeping Adjusted EBITDA, capital expenditure, tax rate, and Free Cash Flow guidance unchanged.
Claritev Corporation held its Annual Meeting on April 29, 2026, where stockholders approved an amendment to the 2020 Omnibus Incentive Plan that increases the common stock reserved under the plan by an additional 2,375,000 shares. Stockholders also elected four Class III directors to the Board and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026. In advisory voting, stockholders approved the compensation of the named executive officers and supported the incentive plan amendment, indicating broad backing for the company’s current governance and compensation structure.
Claritev Corporation used its 2026 Investor Day to outline its strategy, financial guidance, and long-term goals for its healthcare cost-management and analytics platform. Management highlighted core businesses in claims intelligence, network solutions, and payment and revenue integrity, plus growth in data and analytics, international markets, and services.
For FY 2026, Claritev projects revenue of $980 million to $1 billion and Adjusted EBITDA of $605 million to $615 million, with total capital spend of $160 million to $170 million, an effective tax rate of 24% to 28%, and free cash flow of $0 to $10 million.
The company’s Vision 2030 model contemplates revenue of $1.3 billion and Adjusted EBITDA of $800 million, targeting an Adjusted EBITDA margin of roughly 61% to 64% and a path to reduce net leverage toward about 5.0x while increasing levered free cash flow.
Claritev Corporation reported Q4 2025 revenue of $246.6 million, up 6.2% from Q4 2024, and narrowed its quarterly net loss to $80.6 million. Adjusted EBITDA for Q4 was $151.3 million with a 61.4% margin, and free cash flow improved to $36.4 million.
For full-year 2025, revenue reached $965.4 million, a 3.7% increase, while the net loss shrank sharply to $284.3 million from $1.65 billion. Full-year Adjusted EBITDA rose to $602.6 million, and operating cash flow was $117.3 million.
The company issued 2026 guidance with revenue between $980 million and $1 billion, Adjusted EBITDA of $605 million to $615 million, capital expenditures of $160 million to $170 million, and free cash flow between $0 million and $10 million. The board also approved a five-year share repurchase program authorizing up to $75 million of Class A common stock, capped at $20 million per year and funded from cash on hand and operations.
Claritev Corporation reported that Dale White, its former Chief Executive Officer and Executive Chair and currently a director, will end his role as a strategic advisor to the company effective December 31, 2025. He has served in this advisory capacity since stepping down as Executive Chair on December 31, 2024. The company waived its contractual right to 30 days' written notice for ending the advisory role, and no additional compensation is due to Mr. White for this service. Mr. White will continue to serve on Claritev's board of directors.
Claritev Corporation disclosed that affiliates of Hellman & Friedman sold 1,500,000 shares of its Class A common stock in an underwritten secondary offering at $51.50 per share. The Company did not sell any shares and received no proceeds from this transaction.
The Selling Stockholders granted the underwriters a 30-day option to purchase up to 225,000 additional shares. Barclays Capital, Guggenheim Securities, and Wells Fargo Securities acted as joint bookrunners. The offering closed on November 14, 2025. The agreement includes customary representations, warranties, conditions, termination provisions, and indemnification.
Claritev Corporation furnished a Form 8-K to announce it issued a press release reporting financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The information under Item 2.02, including Exhibit 99.1, is furnished and not filed under the Exchange Act and is not subject to Section 18 liability. The filing also lists Exhibit 104 for the cover page Inline XBRL data.
Claritev Corporation renewed contracts with its ten largest clients during 2025, a group that represented approximately 70% of total 2024 revenues. The renewals include automatically renewing agreements that were each renewed for one year.
Excluding clients with automatic one-year renewals, these largest clients accounted for approximately 57% of 2024 revenues. Within this group, the weighted average contract term is greater than three years, excluding the one-year automatic renewals. Claritev highlights continued focus on affordability, transparency, and quality through technology and AI across its enterprise platform.